Applied BioCode Stock

Applied BioCode Liabilities

The The Liabilities of Applied BioCode (6598.TW) as of Sep 6, 2026 is 369.49 M TWD. In the previous year, The Liabilities was 336.07 M TWD — a change of 9.94% (higher).

Liabilities

369.49 MTWD

YoY

9.94%

Last updated:

In 2026, Applied BioCode's total liabilities amounted to 369.49 M TWD, a 9.94% difference from the 336.07 M TWD total liabilities in the previous year.

The Applied BioCode Liabilities history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Liabilities
Date
Liabilities
Jan 1, 2018
81.35 M TWD
Jan 1, 2019
188.36 M TWD
Jan 1, 2020
140.23 M TWD
Jan 1, 2021
116.01 M TWD
Jan 1, 2022
396.38 M TWD
Jan 1, 2023
332.22 M TWD
Jan 1, 2024
336.07 M TWD
Jan 1, 2025
369.49 M TWD
The Applied BioCode Liabilities history
YEARLiabilitiesYoY
369.49 MTWD+9.94%
336.07 MTWD+1.16%
332.22 MTWD-16.19%
396.38 MTWD+241.68%
116.01 MTWD-17.27%
140.23 MTWD-25.55%
188.36 MTWD+131.55%
81.35 MTWD+34.89%
60.30 MTWD+17.84%
51.17 MTWD+25.81%
40.68 MTWD+4.37%
38.97 MTWD
Access this data via the Eulerpool API

Applied BioCode Stock analysis

What does Applied BioCode do? Applied BioCode Corp is a California-based company that focuses on the development and marketing of diagnostic instruments and tests. The company was founded in 2004 by an experienced management team and has since developed a number of groundbreaking technologies to improve the diagnosis of diseases such as cancer, infectious diseases, and autoimmune diseases. The business model of Applied BioCode Corp is based on the development of innovative diagnostic instruments and test systems based on proprietary technologies. The company has a strong partnership with a leading manufacturer of diagnostic automation systems, allowing a wide range of tests for various diseases to be offered. Applied BioCode Corp also works closely with leading research and development organizations to leverage the latest insights in the field of diagnostics. One of the divisions of Applied BioCode is molecular diagnostics, which is an essential component of modern medicine. Molecular diagnostics enables the detection of genetic changes and deviations related to diseases. Applied BioCode's technology allows for rapid and precise identification of pathogens in clinical samples such as blood, urine, and tissue samples. Another important area for Applied BioCode is infectious disease diagnostics. The company has developed a range of test systems based on a variety of infectious diseases such as influenza, tuberculosis, and sexually transmitted diseases such as chlamydia and gonorrhea. These tests can be performed individually or as a group to facilitate disease diagnosis and improve treatment. Applied BioCode also offers tests for the detection of oncological markers. These tests are crucial for the early detection of cancer and monitoring the treatment of cancer patients. Applied BioCode's technology enables rapid and precise identification of cancer cells in blood or tissue, which can improve the effectiveness of treatment. Another important product of Applied BioCode is the BioCode Analyzer, an automated diagnostic instrument. The BioCode Analyzer is a high-throughput system capable of performing multiple tests simultaneously. The analyzer is equipped with a disposable chip that allows for quick and easy diagnosis. This makes the BioCode Analyzer a powerful tool for laboratory automation, providing fast and accurate diagnosis for a variety of diseases. Applied BioCode is also dedicated to researching and developing new technologies. The company has an active pipeline of new products and technologies to further improve diagnostic accuracy and the number of feasible tests. Applied BioCode is also developing new applications for its technologies to improve the diagnosis and treatment of diseases in various ways. In summary, Applied BioCode Corp plays an important role in the field of diagnostic technology. The company has developed a wide range of innovative diagnostic tests and instruments that enable diseases to be quickly and accurately detected. With its strong partnership with leading diagnostic automation system manufacturers and research organizations, Applied BioCode will continue to stay at the forefront and improve diagnostic practice. Applied BioCode is one of the most popular companies on Eulerpool.

Liabilities Details

Assessing Applied BioCode's Liabilities

Applied BioCode's liabilities constitute the company's financial obligations and debts owed to external parties and stakeholders. They are categorized into current liabilities, due within a year, and long-term liabilities, which are due over a longer period. A detailed assessment of these liabilities is crucial for evaluating Applied BioCode's financial stability, operational efficiency, and long-term viability.

Year-to-Year Comparison

By comparing Applied BioCode's liabilities year-over-year, investors can identify trends, shifts, and anomalies in the company’s financial positioning. A decrease in total liabilities often signals financial strengthening, while an increase might indicate enhanced investments, acquisitions, or potential financial strain.

Impact on Investments

Applied BioCode's total liabilities play a significant role in determining the company's leverage and risk profile. Investors and analysts examine this aspect meticulously to ascertain the firm’s ability to meet its financial obligations, which influences investment attractiveness and credit ratings.

Interpreting Liability Fluctuations

Shifts in Applied BioCode’s liability structure indicate changes in its financial management and strategy. A reduction in liabilities reflects efficient financial management or debt payoffs, while an increase may suggest expansion, acquisition activities, or accruing operational expenses, each carrying distinct implications for investors.

Frequently Asked Questions about Applied BioCode stock

The Liabilities of Applied BioCode is 369.49 M TWD in 2026.

The Liabilities of Applied BioCode changed from 336.07 M TWD to 369.49 M TWD, representing a 9.94% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of The Liabilities Applied BioCode since 2006 – with annual values, charts, and detailed analysis.

The Liabilities's TWD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track The Liabilities's Applied BioCode historically and in real time.

Access this data via the Eulerpool API

Balance Sheet — Applied BioCode

All Key Metrics — Applied BioCode